Therapeutic Areas We Serve

Kerevna supports clinical development across more than a dozen therapeutic areas, helping sponsors bring breakthrough therapies to life.

Cardiovascular

We conduct multicenter cardiovascular studies focused on hypertension, heart failure, arrhythmias, and vascular interventions, ensuring patient safety and long-term efficacy.

Oncology

Our oncology trials span solid tumors and hematologic malignancies, incorporating biomarker strategies, precision therapies, and global regulatory expertise.

Pediatrics

We support pediatric trials with ethical frameworks, child-friendly protocols, and safety-focused endpoints across rare and common childhood conditions.

Rare Diseases

From genetic disorders to orphan indications, we offer personalized, flexible operations for rare disease research, including patient advocacy alignment.

Diabetology

Our end-to-end management of diabetes studies covers glucose monitoring, insulin therapies, and lifestyle intervention programs for Type 1 and 2.

Vaccines

Kerevna supports vaccine development across age groups and regions with expertise in enrollment, safety monitoring, and adverse event tracking.

Respiratory

We run trials for asthma, COPD, COVID-19, and lung fibrosis, using pulmonary function testing, imaging, and biomarker-driven endpoints.

CNS & Neurology

Kerevna delivers trials in Alzheimer’s, Parkinson’s, MS, epilepsy, and psychiatric disorders with protocol design adapted for cognitive and behavioral endpoints.

Gastroenterology & Hepatology

Our trials cover IBD, IBS, liver fibrosis, hepatitis, and GI oncology with advanced imaging, patient-reported outcomes, and digital diary systems.

Ophthalmology

We support eye care trials for AMD, glaucoma, dry eye, and rare ocular diseases, managing imaging protocols and ophthalmic equipment vendors.

Infectious Diseases

From HIV and hepatitis to emerging pandemics, we lead ID trials with rapid-start capabilities, diagnostic integration, and real-world data usage.

Cell & Gene Therapy

Our experts manage the regulatory and operational demands of CGT trials, including long-term follow-up, vector monitoring, and patient logistics.